Nomenclature for alleles of the thiopurine methyltransferase gene

Pharmacogenetics and Genomics

Volumn 23, Issue 4, 2013, Pages 242-248

  Appell, Malin L ^a   Berg, Jonathan ^b   Duley, John ^f   Evans, William E ^g   Kennedy, Martin A ^k   Lennard, Lynne ^c   Marinaki, Tony ^d   McLeod, Howard L ^h   Relling, Mary V ^g   Schaeffeler, Elke ^l   Schwab, Matthias ^l,m   Weinshilboum, Richard ⁱ   Yeoh, Allen E J ⁿ   McDonagh, Ellen M ^j   Hebert, Joan M ^j   Klein, Teri E ^j   Coulthard, Sally A ^e  

^a LINKÖPING UNIVERSITY   (Sweden)

^b CITY HOSPITAL   (United Kingdom)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

^d GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^e NEWCASTLE UNIVERSITY   (United Kingdom)

^f UNIVERSITY OF QUEENSLAND   (Australia)

^g ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^h University of North Carolina   (United States)

ⁱ MAYO GRADUATE SCHOOL   (United States)

^j STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k UNIVERSITY OF OTAGO   (New Zealand)

^l DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^m UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

ⁿ NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

more..

Author keywords

allele; nomenclature; pharmacogenetics; thiopurine methyltransferase

Indexed keywords

AZATHIOPRINE; MERCAPTOPURINE; THIOPURINE METHYLTRANSFERASE; TIOGUANINE;

ACUTE LEUKEMIA; ALLELE; ARTICLE; DNA FLANKING REGION; ENTERITIS; ENZYME ACTIVITY; EXON; GENE LOCATION; GENE MAPPING; GENE SEQUENCE; GENETIC VARIABILITY; HUMAN; IMMUNOREGULATION; MEDLINE; NOMENCLATURE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84874931583     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e32835f1cc0     Document Type: Article

References (58)

1. Elion GB, Hitchings GH, Vanderwerff H. Antagonists of nucleic acid derivatives. VI. Purines. J Biol Chem 1951; 192:505-518.
2. Burchenal JH, Murphy ML, Ellison RR, Sykes MP, Tan TC, Leone LA, et al. Clinical evaluation of a new antimetabolite, 6-mercaptopurine, in the treatment of leukemia and allied diseases. Blood 1953; 8:965-999.
3. Fotoohi AK, Coulthard SA, Albertioni F. Thiopurines: factors influencing toxicity and response. Biochem Pharmacol 2010; 79:1211-1220.
4. Coulthard S. Mechanism of thiopurine action. J Braz Med Assoc 2012; 58:18-23.
5. Karran P. Thiopurines, DNA damage, DNA repair and therapy-related cancer. Br Med Bull 2006; 79-80:153-170.
6. Dervieux T, Blanco JG, Krynetski EY, Vanin EF, Roussel MF, Relling MV. Differing contribution of thiopurine methyltransferase to mercaptopurine versus thioguanine effects in human leukemic cells. Cancer Res 2001; 61:5810-5816.
7. Coulthard SA, Hogarth LA, Little M, Matheson EC, Redfern CP, Minto L, et al. The effect of thiopurine methyltransferase expression on sensitivity to thiopurine drugs. Mol Pharmacol 2002; 62:102-109.
8. Tiede I, Fritz G, Strand S, Poppe D, Dvorsky R, Strand D, et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest 2003; 111:1133-1145.
9. Poppe D, Tiede I, Fritz G, Becker C, Bartsch B, Wirtz S, et al. Azathioprine suppresses ezrin-radixin-moesin-dependent T cell-APC conjugation through inhibition of Vav guanosine exchange activity on Rac proteins. J Immunol 2006; 176:640-651.
10. Bourgine J, Garat A, Allorge D, Crunelle-Thibaut A, Lo-Guidice JM, Colombel JF, et al. Evidence for a functional genetic polymorphism of the Rho-GTPase Rac1. Implication in azathioprine response? Pharmacogenet Genomics 2011; 21:313-324.
11. Weinshilboum R, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980; 32:651-662.
12. Lennard L, Lilleyman JS, Van Loon J, Weinshilboum RM. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet 1990; 336:225-229.
13. Krynetski EY, Schuetz JD, Galpin AJ, Pui CH, Relling MV, Evans WE. A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase. Proc Natl Acad Sci USA 1995; 92:949-953.
14. Tai HL, Krynetski EY, Yates CR, Loennechen T, Fessing MY, Krynetskaia NF, et al. Thiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians. Am J Hum Genet 1996; 58:694-702.
15. Lee D, Szumlanski C, Houtman J, Honchel R, Rojas K, Overhauser J, et al. Thiopurine methyltransferase pharmacogenetics. Cloning of human liver cDNA and a processed pseudogene on human chromosome 18q21.1. Drug Metab Dispos 1995; 23:398-405.
16. Spire-Vayron de la Moureyre C, Debuysere H, Mastain B, Vinner E, Marez D, Lo Guidice JM, et al. Genotypic and phenotypic analysis of the polymorphic thiopurine S-methyltransferase gene (TPMT) in a European population. Br J Pharmacol 1998; 125:879-887.
17. Ameyaw MM, Collie-Duguid ES, Powrie RH, Ofori-Adjei D, McLeod HL. Thiopurine methyltransferase alleles in British and Ghanaian populations. Hum Mol Genet 1999; 8:367-370.
18. McLeod HL, Pritchard SC, Githanga J, Indalo A, Ameyaw MM, Powrie RH, et al. Ethnic differences in thiopurine methyltransferase pharmacogenetics: evidence for allele specificity in Caucasian and Kenyan individuals. Pharmacogenetics 1999; 9:773-776.
19. Oliveira E, Quental S, Alves S, Amorim A, Prata MJ. Do the distribution patterns of polymorphisms at the thiopurine S-methyltransferase locus in sub-Saharan populations need revision? Hints from Cabinda and Mozambique. Eur J Clin Pharmacol 2007; 63:703-706.
20. Schaeffeler E, Zanger UM, Eichelbaum M, Asante-Poku S, Shin JG, Schwab M. Highly multiplexed genotyping of thiopurine s-methyltransferase variants using MALD-TOF mass spectrometry: reliable genotyping in different ethnic groups. Clin Chem 2008; 54:1637-1647.
21. Wang L, Pelleymounter L, Weinshilboum R, Johnson JA, Hebert JM, Altman RB, et al. Very important pharmacogene summary: thiopurine S-methyltransferase. Pharmacogenet Genomics 2010; 20:401-405.
22. Nelson MR, Wegmann D, Ehm MG, Kessner D, St Jean P, Verzilli C, et al. An abundance of rare functional variants in 202 drug target genes sequenced in 14, 002 people. Science 2012; 337:100-104.
23. Evans WE, Horner M, Chu YQ, Kalwinsky D, Roberts WM. Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia. J Pediatr 1991; 119:985-989.
24. Relling MV, Hancock ML, Rivera GK, Sandlund JT, Ribeiro RC, Krynetski EY, et al. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst 1999; 91:2001-2008.
25. Relling MV, Pui CH, Cheng C, Evans WE. Thiopurine methyltransferase in acute lymphoblastic leukemia. Blood 2006; 107:843-844.
26. Stanulla M, Schaeffeler E, Flohr T, Cario G, Schrauder A, Zimmermann M, et al. Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia. Jama 2005; 293:1485-1489.
27. Lennard L, Gibson BE, Nicole T, Lilleyman JS. Congenital thiopurine methyltransferase deficiency and 6-mercaptopurine toxicity during treatment for acute lymphoblastic leukaemia. Arch Dis Child 1993; 69:577-579.
28. Relling MV, Gardner EE, Sandborn WJ, Schmiegelow K, Pui CH, Yee SW, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin Pharmacol Ther 2011; 89:387-391.
29. White JA, McAlpine PJ, Antonarakis S, Cann H, Eppig JT, Frazer K, et al. Guidelines for human gene nomenclature (1997). HUGO Nomenclature Committee. Genomics 1997; 45:468-471.
30. Antonarakis SE. Recommendations for a nomenclature system for human gene mutations. Nomenclature Working Group. Hum Mutat 1998; 11:1-3.
31. Den Dunnen JT, Antonarakis SE. Nomenclature for the description of human sequence variations. Hum Genet 2001; 109:121-124.
32. Sasaki T, Goto E, Konno Y, Hiratsuka M, Mizugaki M. Three novel single nucleotide polymorphisms of the human thiopurine S-methyltransferase gene in Japanese individuals. Drug Metab Pharmacokinet 2006; 21:332-336.
33. Schaeffeler E, Eichelbaum M, Reinisch W, Zanger UM, Schwab M. Three novel thiopurine S-methyltransferase allelic variants (TPMT&z.ast;20, &z.ast;21, &z.ast;22)-association with decreased enzyme function. Hum Mutat 2006; 27:976.
34. Ujiie S, Sasaki T, Mizugaki M, Ishikawa M, Hiratsuka M. Functional characterization of 23 allelic variants of thiopurine S-methyltransferase gene (TPMT&z.ast;2-&z.ast;24). Pharmacogenet Genomics 2008; 18:887-893.
35. Garat A, Cauffiez C, Renault N, Lo-Guidice JM, Allorge D, Chevalier D, et al. Characterisation of novel defective thiopurine S-methyltransferase allelic variants. Biochem Pharmacol 2008; 76:404-415.
36. Appell ML, Wennerstrand P, Peterson C, Hertervig E, Martensson LG. Characterization of a novel sequence variant, TPMT&z.ast;28, in the human thiopurine methyltransferase gene. Pharmacogenet Genomics 2010; 20:700-707.
37. Landy J, Bhuva N, Marinaki A, Mawdsley J. Novel thiopurine methyltransferase variant TPMT&z.ast;28 results in a misdiagnosis of TPMT deficiency. Inflamm Bowel Dis 2010; 17:1441-1442.
38. Spire-Vayron de la Moureyre C, Debuysere H, Sabbagh N, Marez D, Vinner E, Chevalier ED, et al. Detection of known and new mutations in the thiopurine S-methyltransferase gene by single-strand conformation polymorphism analysis. Hum Mutat 1998; 12:177-185.
39. Yates CR, Krynetski EY, Loennechen T, Fessing MY, Tai HL, Pui CH, et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 1997; 126:608-614.
40. Salavaggione OE, Wang L, Wiepert M, Yee VC, Weinshilboum RM. Thiopurine S-methyltransferase pharmacogenetics: variant allele functional and comparative genomics. Pharmacogenet Genomics 2005; 15:801-815.
41. Tai HL, Krynetski EY, Schuetz EG, Yanishevski Y, Evans WE. Enhanced proteolysis of thiopurine S-methyltransferase (TPMT) encoded by mutant alleles in humans (TPMT&z.ast;3A, TPMT&z.ast;2): mechanisms for the genetic polymorphism of TPMT activity. Proc Natl Acad Sci USA 1997; 94:6444-6449.
42. Szumlanski C, Otterness D, Her C, Lee D, Brandriff B, Kelsell D, et al. Thiopurine methyltransferase pharmacogenetics: human gene cloning and characterization of a common polymorphism. DNA Cell Biol 1996; 15:17-30.
43. Otterness D, Szumlanski C, Lennard L, Klemetsdal B, Aarbakke J, Park-Hah JO, et al. Human thiopurine methyltransferase pharmacogenetics: gene sequence polymorphisms. Clin Pharmacol Ther 1997; 62:60-73.
44. Colleoni L, Kapetis D, Maggi L, Camera G, Canioni E, Cavalcante P, et al. A new thiopurine S-methyltransferase haplotype associated with intolerance to azathioprine. J Clin Pharmacol 2012. doi: 10.1177/0091270011435989. [Epub ahead of print].
45. Otterness D, Szumlanski C, Weinshilboum R. Human thiopurine methyltransferase pharmacogenetics: identification of a novel variant allele. J Invest Med 1996; 44:248A.
46. Hon YY, Fessing MY, Pui CH, Relling MV, Krynetski EY, Evans WE. Polymorphism of the thiopurine S-methyltransferase gene in African-Americans. Hum Mol Genet 1999; 8:371-376.
47. Schaeffeler E, Fischer C, Brockmeier D, Wernet D, Moerike K, Eichelbaum M, et al. Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants. Pharmacogenetics 2004; 14:407-417.
48. Colombel JF, Ferrari N, Debuysere H, Marteau P, Gendre JP, Bonaz B, et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 2000; 118:1025-1030.
49. Hamdan-Khalil R, Allorge D, Lo-Guidice JM, Cauffiez C, Chevalier D, Spire C, et al. In vitro characterization of four novel non-functional variants of the thiopurine S-methyltransferase. Biochem Biophys Res Commun 2003; 309:1005-1010.
50. Schaeffeler E, Stanulla M, Greil J, Schrappe M, Eichelbaum M, Zanger UM, et al. A novel TPMTmissense mutation associated with TPMTdeficiency in a 5-year-old boy with ALL. Leukemia 2003; 17:1422-1424.
51. Lindqvist M, Haglund S, Almer S, Peterson C, Taipalensu J, Hertervig E, et al. Identification of two novel sequence variants affecting thiopurine methyltransferase enzyme activity. Pharmacogenetics 2004; 14:261-265.
52. Hamdan-Khalil R, Gala JL, Allorge D, Lo-Guidice JM, Horsmans Y, Houdret N, et al. Identification and functional analysis of two rare allelic variants of the thiopurine S-methyltransferase gene, TPMT&z.ast;16 and TPMT&z.ast;19. Biochem Pharmacol 2005; 69:525-529.
53. Lindqvist M, Skoglund K, Karlgren A, Soderkvist P, Peterson C, Kidhall I, et al. Explaining TPMT genotype/phenotype discrepancy by haplotyping of TPMT&z.ast;3A and identification of a novel sequence variant, TPMT&z.ast;23. Pharmacogenet Genomics 2007; 17:891-895.
54. Kham SK, Soh CK, Aw DC, Yeoh AE. TPMT&z.ast;26 (208F-L), a novel mutation detected in a Chinese. Br J Clin Pharmacol 2009; 68:120-123.
55. Feng Q, Vannaprasaht S, Peng Y, Angsuthum S, Avihingsanon Y, Yee VC, et al. Thiopurine S-methyltransferase pharmacogenetics: functional characterization of a novel rapidly degraded variant allozyme. Biochem Pharmacol 2010; 79:1053-1061.
56. Lee CK, Loh TP, Wong ST, Lee HK, Huan PT, Chiu LL, et al. Detection of a novel single nucleotide polymorphism of the human thiopurine s-methyltransferase gene in a Chinese individual. Drug Metab Pharmacokinet 2012; 27:559-561.
57. Lennard L, Cartwright CS, Wade R, Richards SM, Vora A. Thiopurine methyltransferase genotype-phenotype discordance, and thiopurine active metabolite formation, in childhood acute lymphoblastic leukaemia. Br J Clin Pharmacol 2012. doi: 10.1111/bcp.12066. [Epub ahead of print].
58. Whirl-Carrillo M, McDonagh EM, Hebert JM, Gong L, Sangkuhl K, Thorn CF, et al. Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther 2012; 92:414-417.